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To test the hypothesis that suppression of ventricular arrhythmias 
by antiarrhythmic drugs after myocardial infarction improves 
survival, the Cardiac Arrhythmia Suppression Trial (CAST) was 
initiated. Suppression was evaluated before randomization during 
an open label titration period. Patients whose arrhythmias were 
suppressed were randomized in the main study and those whose 
arrhythmias were partially suppressed were randomized in a 
substudy. Overall survival and survival free of arrhythmic death 
or cardiac arrest were higher in patients treated with encainide or 
f1ecainide than in patients treated with placebo. However, the 
death rate in patients randomized to placebo therapy was lower 
than expected. This report describes the survival experience of all 
patients enrolled in CAST and compares it with mortality in other 
studies of patients with ventricular arrhythmias after myocardial 
infarction. 
As of April 18, 1989,2,371 patients had enrolled in CAST and 
entered prerandomization, open label titration: 1,913 (81 %) were 
randomized to double-blind, placebo-controlled therapy (1,775 
patients whose arrhythmias were suppressed and 138 patients 
whose arrhythmias were partially suppressed during open label 
titration); and 458 patients (19%) were not randomized because 
they were still in titration, had died during titration or had 
withdrawn. Including all patients who enrolled in CAST, the 
actuarial (Kaplan-Meier) estimate of I-year mortality was 10.3%. 
To estimate the "natural" mortality rate of patients enrolled in 
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CAST, an analysis was done that adjusted for deaths that might be 
attributable to encainide or f1ecainide treatment either during 
prerandomization, open label drug titration or after randomiza-
tion. Because the censoring procedure excluded patients treated 
with encainide or f1ecainide after randomization, the mortality 
estimate will be less than the unadjusted mortality estimate of 
10.3%. A minimall-year "natural" mortality rate of 6.3% was 
estimated by assuming that all deaths during open label titration 
with encainide or f1ecainide were due to drug treatment and that 
after randomization all excess mortality in the group randomized 
to active treatment was also due to drug effect. A maximal I-year 
"natural" mortality rate of 8.4% was estimated by assuming that 
no deaths during open label titration with encainide or f1ecainide 
were due to drug treatment and that after randomization all 
excess mortality in the group randomized to active treatment was 
due to drug effect. Thus, the "natural" overall mortality rate in 
CAST, falling somewhere between 6.3% and 8.4%, is similar to 
rates observed in other postinfarction natural history studies, 
suggesting that the low mortality rate in the group randomized to 
placebo is largely due to the process of selecting only those 
enrolled patients for the randomized phase of CAST whose 
ventricular arrhythmias were suppressed in the prerandomization 
open label titration phase. 
(J Am Coll CardioI1991;18:14-9) 
testing the hypothesis that suppression of asymptomatic or 
mildly symptomatic ventricular arrhythmias after myocar-
dial infarction reduces the incidence of arrhythmic cardiac 
death (1). The study is unique among antiarrhythmic drug 
trials because only patients whose ventricular arrhythmias 
are suppressed are randomized to receive active drug or 
placebo and are included in outcome analysis. Although not 
included in the main CAST study (1), patients with partially 
suppressed arrhythmias are similarly randomized and fol-
lowed up in a sub study . Patients whose ventricular arrhyth-
mias increase during open label drug titration or who cannot 
tolerate drug therapy are not randomized to receive blinded, 
placebo-controlled drug therapy. 
The preliminary CAST report (1) showed that rates of 
both overall survival and survival free of arrhythmic death or 
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cardiac arrest in the group treated with placebo were supe-
rior to rates in the group treated with encainide or flecainide. 
Over an average 10 month follow-up period, the crude total 
mortality in the encainide- and flecainide-treated patients 
was 7.7% compared with 3.0% in the placebo control pa-
tients (relative risk 2.5, 95% confidence interval 1.6 to 4.1). 
Similarly, deaths from arrhythmia and nonfatal cardiac ar-
rests occurred in 4.5% of the encainide- and flecainide-
treated patients and in 1.2% of the placebo-treated control 
patients (relative risk 3.6, 95% confidence interval 1.8 to 
7.6). The relatively low death rate in patients randomized to 
double-blind therapy was, however, substantially less than 
one might have expected (2-14). 
The preliminary CAST report provided no information on 
25% of the patients who signed consent but were not 
randomized in the main study, including 6% who had partial 
suppression of their arrhythmias and entered a sub study and 
19% who were not randomized to drug therapy. This report 
extends the preliminary report by describing the clinical 
characteristics and outcome of all patients, both randomized 
and nonrandomized, who enrolled in CAST and entered drug 
titration before April 18, 1989, the date encainide and 
flecainide were dropped from the study, and compares 
CAST with other studies of sudden cardiac death and overall 
mortality in patients with ventricular premature depolariza-
tions after myocardial infarction. When the mortality expe-
rience of the entire CAST popUlation is examined, CAST 
patients do indeed appear similar to those previously re-
ported with ventricular ectopic activity after myocardial 
infarction. 
Methods 
Eligibility of patients. The design of CAST has been 
previously described in detail (1). Patients were eligible to be 
screened for CAST enrollment between 6 days and 2 years 
after documented myocardial infarction. An ambulatory 
electrocardiographic (ECG) Holter recording was obtained 
with a minimum of 18 h of analyzable data; patients qualified 
if they had an average of ~6 ventricular premature depolar-
izationslh. To enroll potentially high risk patients and main-
tain adequate statistical power, a left ventricular ejection 
fraction of :::;0.55 was required for inclusion in the study if 
the patient was enrolled within 90 days of myocardial 
infarction; the requirement was reduced to :::;0.40 if the 
recording was obtained between 90 days and 2 years after 
the qualifying infarction. Patients were excluded from the 
trial if they had severely symptomatic ventricular arrhyth-
mias (incapacitating symptoms, syncope or presyncope) or 
had ~ 15 consecutive ventricular premature depolarizations 
at a rate of ~120 beats/min. The protocol was approved by 
each participating clinical center's Institutional Review 
Board. CAST was monitored independently by an external 
Data and Safety Monitoring Board. Written, informed con-
sent was obtained from all patients who participated in the 
study. 
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Drug titration. Patients were treated with up to two 
doses of three drugs (encainide, flecainide or moricizine) in 
unblinded, open label titration. The criteria for suppression 
were ~80% reduction in the frequency of ventricular prema-
ture depolarizations and ~90% reduction in runs of unsus-
tained ventricular tachycardia, as measured by 24 h ambu-
latory ECG recordings obtained 4 to 10 days after the start of 
each drug dose. Doses 1 and 2 for encainide were, respec-
tively, 35 and 50 mg three times a day; for flecainide, 100 and 
150 mg twice a day and for moricizine, 200 and 250 mg three 
times a day. Unblinded, open label titration was discontin-
ued and the patient was eligible for randomization to blinded 
therapy as soon as a drug and dose were found that were well 
tolerated and suppressed the ventricular arrhythmia. If only 
partial suppression was achieved and the drug was well 
tolerated, the patient entered blinded therapy in a substudy. 
At the time of randomization, the patient was assigned to 
receive either the active drug and dose that suppressed (or 
for the sub study , partially suppressed) the ventricular ec-
topic activity or a matching placebo. The nonrandomized 
group consisted of individuals who were still in the open 
label titration phase; whose arrhythmia increased during this 
phase; or who were intolerant of drugs, died before random-
ization or withdrew for any reason. 
FoUow-up. Patients whose arrhythmias were success-
fully suppressed or partially suppressed were scheduled for 
postrandomization follow-up visits at 4 month intervals. 
Nonrandomized patients were followed up by telephone at 6 
month intervals. This report is based on the March 15, 1990 
version of the CAST data file. The primary CAST end point 
was arrhythmic death or cardiac arrest (1). All primary end 
points in randomized patients were reviewed by the Events 
Committee, a subcommittee of CAST investigators who did 
not know the patients' treatment assignment. 
Statistical analyses. Contributions to overall mortality 
came from deaths 1) during titration, 2) after titration during 
randomized therapy, and 3) after titration among the non-
randomized patients. An estimate of mortality after titration 
during randomized therapy is accomplished by restricting 
the analysis to patients randomized to placebo. No adjust-
ment is needed for contributions to mortality after titration in 
the nonrandomized patients because they did not receive the 
study drug after titration was completed. However, because 
some deaths that occurred during titration (before random-
ization to blinded therapy) may also have been the result of 
antiarrhythmic drug use, further adjustment of the mortality 
estimate must be made for deaths that occurred in this 
phase. An unbiased estimate of natural mortality during 
titration is not possible because there was no placebo 
control. Thus, by assuming that all deaths occurring during 
titration with encainide or flecainide were due to encainide 
or flecainide, censoring (that is, assuming that the patient 
was simply lost to further follow-up at the time of death) 
patients at the time events occurred during titration with or 
within 10 days of discontinuing encainide or flecainide 
provides a lower boundary on the estimated "natural" 
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mortality. An upper boundary can be achieved by assuming 
that all of the deaths during titration were "natural" (that is, 
not due to encainide or ftecainide). Based on the assumption 
(the aim of randomization) that. except for drug effects, 
mortality was the same in the patients treated with active 
drug and in those treated with placebo, the contribution of 
the placebo-treated patients to the mortality estimate was 
given a twofold weight because these patients represent both 
themselves and their randomized counterparts. Event rates 
were computed by using the Kaplan-Meier method. The 
weighting procedure provides an unbiased estimate of upper 
and lower boundaries for overall "natural" mortality. 
Deaths that occurred during titration with moricizine were 
not censored because there is no evidence that this drug 
affects mortality. 
Because the moricizine arm of CAST continues, some 
restrictions on the dissemination of end point data involving 
moricizine are critical to maintain integrity of the trial, which 
is ongoing and remains double-blinded. Overall estimates of 
mortality that include moricizine-treated patients are permit-
ted (as in this report) but individual estimates of mortality for 
moricizine-treated patients and their placebo-treated coun-
terparts and explicit enumeration of overall events or of 
events occurring during active therapy are not permitted 
because the interim moricizine results could be determined 
by review of all the CAST publications. It is believed that 
this method of analysis allows for the maximal use of the 
early CAST data, including placebo information and general 
overall mortality estimates, while protecting the integrity of 
the ongoing trial. 
Results 
Demographics. As of April 18, 1989, 2,371 patients en-
tered open label titration in CAST. The baseline character-
istics of all patients who enrolled in CAST and underwent 
titration are reviewed in Table 1. Suppression of arrhythmias 
was achieved in 1,775 patients (75%) and partial suppression 
in 138 (6%); 458 patients (19%) were not randomized. 
Follow-up of the randomized patients averaged 9.7 months 
from randomization to blinded therapy with only 4.7% 
withdrawing from blinded therapy follow-up. Among the 
nonrandomized patients who survived ~1O days after com-
pletion of titration, follow-up averaged 8.7 months with 8.5% 
withdrawing from telephone follow-up. The duration of 
titration averaged 21 days. 
Mortality. Of the 2,051 patients who entered open label 
titration and did not enter blinded moricizine therapy (see 
last paragraph under Methods), 183 patients died or experi-
enced cardiac arrest. Sixty-three of these events occurred 
during titration; 93 during randomized therapy with encain-
ide, ftecainide or corresponding placebo and 27 during 
follow-up of nonrandomized patients. Of these 183 deaths 
and cardiac arrests, 168 were classified as cardiac: 122 
arrhythmic deaths/cardiac arrests (67 witnessed deaths, 39 
unwitnessed deaths and 16 resuscitated cardiac arrests) and 
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Table 1. Baseline Characteristics of 2,371 Patients Randomized to 
Open Label Titration on or Before April 18, 1989 
Age (yr) 61.5 ± 9.9 
Male (%) 80.9 
Ejection fraction 0.37 ± 0.11 
VPDIh 124.9 ± 250.2 
Baseline ECG 
PR interval (s) 0.17 ± 0.03 
QRS interval (s) 0.09 ± 0.02 
History before index MI (%) 
CHF 15.4 
Angina 46.5 
Hypertension 31.2 
Prior MI 39.0 
CABG/PTCA 17.4 
History after index MI (%) 
No CHF or NYHA functional class I 84.6 
No angina or Canadian angina class I 89.9 
Thrombolytic therapy 25.7 
PTCA 18.4 
CABG 17.8 
Baseline examination 
Sitting HR (beats/min) 75 ± 13 
Systolic BP (mm Hg) 125 ± 19 
Diastolic BP (mm Hg) 76 ± 10 
Concurrent drugs (%) 
Beta-adrenergic blocker 29.1 
Calcium channel blocker 48.7 
Digitalis 24.3 
Nitrate 46.5 
Diuretic 36.7 
Values are mean values (±SD when appropriate). BP = blood pressure; 
CABG = coronary artery bypass grafting; CHF = congestive heart failure; 
ECG = electrocardiogram; HR = heart rate; MI = myocardial infarction; 
NYHA = New York Heart Association; PTCA = percutaneous transluminal 
coronary angioplasty; VPD = ventricular premature depolarizations; VT = 
ventricular tachycardia. 
46 nonarrhythmic deaths. There were 12 noncardiac deaths 
and 3 deaths that could not be classified. Without adjusting 
for drug effects during or after titration, the I-year incidence 
of arrhythmic death/cardiac arrest was 6.6%; that of death 
due to cardiac but nonarrhythmic causes was 3.0% and that 
of death due to noncardiac causes or unclassified was 0.9%. 
The actuarial I-year all-cause mortality rate for the 2,371 
patients who entered open label titration was 10.3% (Fig. 1). 
By censoring to adjust for deaths that may have been 
attributable to encainide or ftecainide, the estimated lower 
boundary on mortality at 1 year was 6.3% (Fig. 2). By not 
adjusting for deaths occurring during titration (before ran-
domization to blinded therapy) that mayor may not have 
been attributable to encainide or ftecainide, the estimated 
upper boundary on mortality at 1 year was 8.4% (Fig. 2). 
Discussion 
Comparison with previous studies. The reported all-cause 
mortality rate after myocardial infarction ranges from 5% at 
1 year (11) to 30% at 1.5 years (10). Mortality data derived 
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Figure 1. Overall mortality in CAST (censored at 366 days) for all 
patients who entered open label titration. Data are not adjusted for 
drug effects. See text for discussion. 
from previous studies are reviewed in Table 2 to provide 
comparison with the CAST data. The subgroups presented 
were chosen to highlight postmyocardial infarction patients 
with a degree of ventricular arrhythmia that was similar to 
that of patients who participated in CAST. The I-year 10.3% 
mortality estimate for patients who signed consent and 
entered open label titration in the Cardiac Arrhythmia Sup-
pression Trial (CAST) is consistent with results of these 
earlier investigations. In addition, the frequency of death 
from all cardiac causes is modified by many factors includ-
ing, but not limited to, concomitant pharmacologic therapy 
(including antiarrhythmic drugs), the frequency and com-
plexity of ventricular arrhythmia, the degree of left ventric-
ular dysfunction, underlying coronary anatomy and ischemia 
(8,9,12). Furthermore, the I-year estimated 6.6% incidence 
Figure 2. Estimates of the "natural" mortality uncontaminated by 
antiarrhythmic drug effects for patients in CAST from time of entry 
into open label titration (censored at 366 days). The upper curve 
shows the upper boundary of estimated natural mortality, assuming 
that none of the deaths that occurred during titration were due to 
encainide or ftecainide. The lower curve shows the lower boundary 
of estimated natural mortality, assuming that all of the deaths that 
occurred during titration with encainide or ftecainide were due to 
encainide or ftecainide and censoring patients at the time events 
occurred during titration with (or within 10 days of discontinuing) 
these two drugs. See text for discussion. 
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of arrhythmic death/cardiac arrest in the CAST patients 
reported here is also consistent with the previously reported 
frequency of sudden cardiac death in patients with ventric-
ular premature depolarizations after myocardial infarction, 
which ranges from 5% at 1 year (5) to approximately 13% at 
1.5 years (10) (Table 2). 
Factors explaining the low mortality in previous CAST 
report. Because both overall mortality and arrhythmic 
death/cardiac arrest rates were seemingly lower in the CAST 
placebo group than in previous studies, the question has 
been raised whether the CAST population is representative 
of post infarction patients in general (14). However, the death 
rate for all patients who were recruited to CAST, signed 
consent and entered prerandomization open label titration is 
consistent with death rates previously reported. Several 
factors may explain the apparently low death rate for pa-
tients in the initial report (1) of the main CAST results for 
treatment with encainide and ~ecainide: 1) to be random-
ized, patients had to survive the titration phase; 2) prior 
studies may have overestimated the mortality risk for pa-
tients with frequent ventricular ectopic activity because 
these patients may have been more likely than patients 
without arrhythmias to have been treated with antiarrhyth-
mic drugs, and these drugs may have been partly responsible 
for the observed mortality; and 3) patients randomized in 
CAST were selected because they had suppressible ventric-
ular arrhythmias. Indeed, the results suggest that ventricular 
arrhythmia suppression by encainide or fiecainide may itself 
be a marker for improved survival. 
The relative incidence of arrhythmic death and cardiac 
arrest compared with that of nonarrhythmic cardiac death in 
CAST was 2.7: 1 (122 arrhythmic deaths/cardiac arrests and 
46 nonarrhythmic cardiac deaths). This relative incidence is 
notably different from the approximate 0.5-1: 1 ratio ob-
served by Ruberman et al. (5), by the International Mexilet-
ine and Placebo Antiarrhythmic Coronary Trial (IMPACT) 
(11) and by Kostis et al. (13) for the Beta-Blocker Heart 
Attack Trial (BHAT) (Table 2). The reason for the difference 
is not readily explainable but is probably related to differ-
ences in patient selection and in end point definitions. For 
example, the 15.4% incidence of congestive heart failure in 
CAST was higher than the 3.5% incidence in IMPACT (11) 
and 9.8% incidence in BHAT for patients with ;::1 ventricu-
lar premature depolarizations (12). 
Limitations of comparing the CAST with other studies. No 
other study has required suppression of ventricular arrhyth-
mia as a criterion for entry or randomization to a therapeutic 
intervention. Surawicz (15) reviewed the reported incidence 
of sudden cardiac death after myocardial infarction in 21 
studies (25 patient groups) in which the study popUlation 
exceeded 60 patients, average follow-up was ;::12 months 
and the sudden cardiac death rate was either stated or could 
be estimated from the data provided. A computed regression 
line weighted by sample size documents the incidence of 
sudden death to be only 3.6% at 12 months. Unfortunately, 
the regression analysis was not restricted to patients with 
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Table 2. Earlier Studies of Outcome in Patients With Ventricular Premature Depolarizations After Myocardial Infarction 
Investigation 
Coronary Drug Project (3) 
Ruberman et aI. (5) 
Bigger et aI.IMPIR (8) 
MukhaIjiIMILlS (10) 
IMPACT (11) 
Kostis et aI.lBHAT (13) 
CAST (I) 
Current study 
N 
2,7(1.) 
1,739 
766 
533 
630 
113 
3,290 
1,455 
725U 
730§§ 
2,371 
Entry Criteria 
3 mo post-MI 
MI survivors 
Prior MI 
10 days post-MI 
Recent MI 
3 weeks post-MI 
6 days to 2 yr post-
MI 
CAST titrated 
Arrhythmic 
Death! 
Cardiac Arrest 
(sudden death) 
8.9 (36)* 
4.8 (12)t 
12.2 (24)* 
12.8 (l8)§ 
1.3 (9)11 
5.1 (25)** 
9.0 (25)tt 
1.2 (10) 
4.5 (10) 
6.6 (12) 
% Patients (foUow-up mol With 
Nonarrhythmic 
Cardiac Death 
(nonsudden 
death) 
4.6 (l2)t 
2.6 (9)11 
4.5 (25)** 
8.1 (25)tt 
3.0 (12) 
Death 
21.7 (36)* 
9.2 (l2)t 
19.6 (24)* 
29.5 (l8)§ 
4.8 (9)11 
5.4 (9)~ 
10.9 (25)** 
19.9 (25)tt 
3.0 (10) 
7.7 (10) 
10.3 (12) 
*Limited to 314 patients with ~1 VPDI121ead ECG; antiarrhythmic drug use not reported; tlimited to 462 patients with "complex" VPDs (R-on-T, runs ~2, 
multiform or bigeminal VPDs); antiarrhythmic drug use not reported; *limited to 245 patients with ~3 VPDsih; §limited to 78 patients with ~ 10 VPDsih; lilimited 
to 313 placebo-treated patients; 90% had ~1 VPD/24 h; ~these patients had Lown class 2, 4A or 4B VPDs; **limited to 1,640 placebo-treated patients with ~1 
VPDs/h (84%) (1,349 were not receiving an antiarrhythmic drug); ttlimited to 1,640 placebo-treated patients with ~IO VPDsih (13%) (1,349 were not receiving 
an antiarrhythmic drug); Upatients treated with placebo; §§patients treated with encainide or f1ecainide. BHAT = Beta-Blocker Heart Attack Trial; CAST = 
Cardiac Arrhythmia Suppression Trial; ECG = electrocardiogram; IMPACT = International Mexiletine and Placebo Antiarrhythmic Coronary Trial; MI = 
myocardial infarction; MILlS = Multicenter Investigation of the Limitation of Infarct Size; MPIR = Multicenter Post-Infarction Research Group; VPD = 
ventricular premature depolarization. 
ventricular arrhythmias and, given the varied entry criteria 
and follow-up in the pooled investigations, direct compari-
son with the CAST data base is not possible. However, 
because the I-year actuarial mortality for all patients enter-
ing CAST open label titration was 10.3%, the CAST popu-
lation can reasonably be considered a high risk group for 
death after myocardial infarction. 
Role of beta-blockers. Beta-adrenergic blocking agents 
have been shown to decrease the frequency of ventricular 
arrhythmias after myocardial infarction (7,9,12). In the Beta-
Blocker Heart Attack Trial, although 15.4% of patients with 
ventricular premature depolarizations experienced a de-
crease in arrhythmia frequency during propranolol therapy 
(7), Friedman et al. (12) showed that both the patients with 
and those without ventricular arrhythmias received benefit 
from beta-blockade. However, in CAST, because only 
29.1% of patients who entered open label titration were 
receiving a beta-blocker and because randomized and non-
randomized patients had almost equal beta-blocker usage 
(30.2% and 24.5%, respectively), it is unlikely that the low 
event rate in the placebo group was due to the use of these 
drugs. 
Role of thrombolysis, angioplasty and ischemia. Be-
cause thrombolytic therapy improves survival after myocar-
dial infarction (16,17) and because coronary angioplasty also 
benefits selected patients (17,18), the question has been 
raised whether the low mortality in CAST was due to the use 
of these interventions. Indeed, Theroux et al. (19) showed 
that fibrinolysis with or without angioplasty reduced the 
frequency of ventricular premature depolarizations. How-
ever, CAST patients still had significant ventricular ectopic 
activity (125 ventricular premature depolarizationslh). Fur-
thermore, in CAST the frequencies of thrombolytic therapy 
and of angioplasty use were modest (25.7% received throm-
bolytic therapy and 18.4% angioplasty) and also similar in 
the randomized (26.6% and 19.0%, respectively) and non-
randomized (21.8% and 15.9%, respectively) patients. Thus, 
it is unlikely that the low event rate in the placebo group was 
due to the use of these interventions. Furthermore, because 
the treatment for ischemia was the same during and after 
titration, it is also unlikely that a difference in treatment for 
ischemia accounted for the low event rate in the placebo 
group. 
Implications. The probabilities of survival for patients 
who enrolled in CAST and entered open label titration and 
for patients reported on in other studies of mortality after 
myocardial infarction are similar. The low mortality rate in 
patients randomized to the main CAST trial may be ex-
plained by their selection because they had suppressible 
ventricular arrhythmias. This relatively good survival rate 
does not detract from the applicability of CAST findings to 
other patients with ventricular arrhythmias after myocardial 
infarction. Specifically, attempts to suppress ventricular 
premature depolarizations after myocardial infarction by 
treatment with encainide or flecainide cannot be condoned 
because mortality was increased despite the ability of these 
drugs to suppress ventricular arrhythmias. Indeed, the sup-
pression hypothesis itself is called into question because, 
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despite arrhythmia suppression, patients treated with 
encainide or ftecainide experienced greater mortality than 
their counterparts treated with placebo. Furthermore, if the 
treatment of ventricular premature depolarizations in post-
myocardial infarction patients is based on the assumption 
that suppression is beneficial, it makes no sense to continue 
drugs that are not suppressive. The CAST findings suggest 
that the ability to suppress ventricular premature depolar-
izations in postmyocardial infarction patients predicts im-
proved survival independent of antiarrhythmic drug therapy. 
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